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1. Introduction 
Cardiovascular death remains the most frequent cause of mortality of dialysis population. 
Among the risk factor of cardiovascular mortality low blood pressure has been investigated 
by several authors even though not all the author conclude that low blood pressure per se, 
not adjusted for concomitant factors like age, and the presence of diabetes can be seen as 
independent predictor of mortality (Tisler et al., 2003; Iseki et al., 1997; Port et al., 1999). 
In particular, the presence of low blood pressure and the intradialytic fall in the systolic and 
diastolic blood pressure seems to predict mortality in the dialysis population (Sohji et al., 
2004). Some other authors found that not only low predialysis systolic blood pressure but 
also high values (J shape theory) expose patients at higher risk of mortality (Port et al, 1999). 
Nevertheless, the fall in systolic blood pressure seems to be to date the most common 
intradialytic complication accounting for up to 30 % of dialysis related symptoms, despite 
the several improvement of dialysis techniques in terms of biocompatibility of the material 
used, more convection and quality of dialysis fluid. But hypertension is indeed the most 
frequent chronic co morbidity affecting dialysis patients. 
Predialysis hypertension does not prevent hypotension episodes and not having targets for 
blood pressure control will not necessarily reduce its onset. When improved control of 
blood pressure is desired, modifications to the dialysis treatment itself should be considered 
as part of the management strategy (Davenport et al., 2008). 
Hypo- as well hypertension are then the most challenging complications which dialysis has 
to face with. Several strategies are available to prevent hypo and hypertension like longer or 
more frequent dialysis regimen, diffusive-convective therapies, and assessment of dry body 
weight. Not all of them can be used in routine practice due to infrastructural or financial 
constraints while some others give in a certain extent opposite’s effects like assessment of 
dry body weight beneficial for the hypertensive status, but which can lead to an increase of 
intradialytic symptoms (Davenport et al., 2008). Among the tools today available, the 
biofeedback systems, those devices able to adapt the operative condition of dialysis to the 
dynamic changes of the patients status along the dialysis, seems to be promising for 
contributing a step forward in the patients well-being (Locatelli et al., 2005) Among these 
devices the Hemocontrol Biofeedback System (HBS) has been extensively studied by several 
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authors as a tool to contribute in lowering the hypotension incidence but also as a further 
utility to control or normalize the blood pressure. 
This review will summarize all the contributions given by the several studies about the 
cardiovascular stability in HBS dialysis. 
2. HemocontrolTM biofeedback system 
It is well known that blood volume behavior during dialysis is affected by several factors 
among which the ultrafiltration and changes in dialysate sodium level are the most relevant. 
Ultrafiltration should be adapted to the rhythm of plasma water removal respect to the 
patient’s refilling capabilities, but the main limitation relies in the inability to maintain the 
total planned weight loss within the preset dialysis time except for long lasting dialysis 
treatments. The dialysate sodium can also promote the mobilization of water from the 
extravascular space reconstituting the plasma lost during ultrafiltration. Moreover, the 
modification of the intravascular sodium level can increase the activity of the autonomic 
nervous system, with a better hemodynamic response from the peripheral vascular 
resistance. However, the intradialytic sodium balance must be taken under tight control to 
avoid any sodium overload leading in turn a fluid overload especially in the interdialytic 
period. The blood volume control system (Hemocontrol) has been developed bearing in 
mind these three aspects (hemodynamic stability, fluid and sodium balance). The system is 
designed as feedback controller with three controlled variables (blood volume, total weight 
loss and average dialysate sodium level) and two actuators, the ultrafiltration and actual 
dialysate sodium level (Paolini & Bosetto, 1999) (Figure 1). 
 
 
Fig. 1. Schematic representation of the Hemocontrol Biofeedback System. The MIMO 
controller processes three different controlled variables (blood volume reduction, average 
dialysate conductivity, body weight loss) through the errors between the actual and the 
desired values. The two actuators, reacting to the errors, are the actual dialysate 
conductivity and the weight loss rate (Santoro et al., 1998). 
In Particular, the multi-input multi-output controller processes the errors between the 
actual continuously measured values of BV, weight loss and average dialysate sodium 
and their desired values, and reacts by adjusting the ultrafiltration and actual dialysate 
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sodium to keep all the controlled variables as close to the target values as possible, 
however within pre-specified degree of tolerance. The desired blood volume reduction is 
set according to the total amount of fluid to be removed during dialysis (BV/UF volume). 
In fact, the blood volume reduction is a function of the overall water removal (Mancini et 
al, 1995), then its reduction per liters of water removal should be an invariant for any 
patient and then can take into account for the long or short interdialytic period. Since the 
actual dialysate sodium level is adjusted from the controller to regulate the blood volume 
time pattern, another parameter is set at the beginning of dialysis, that is the average 
dialysate sodium level. This value must prevent any sodium overload or abrupt depletion 
during the treatment (Moret et al., 2002). 
All the actuators, that is the ultrafiltration and actual dialysate sodium, are always limited 
within safety operating regions. In particular the ultrafiltration rate is upper limited from 
the max UF rate at the beginning of dialysis to the average weight loss rate at the end and it 
is lower limited by the minimum UF rate (100 mL/h). The maximal initial UF rate is 
prescribed by the nurse according to patients characteristics and it is usually set at a value 
20% to 50% higher than the average UF rate. The dialysate sodium is again upper limited 
from a maxi initial sodium content to the lowest value at the end of the treatment and the 
user can set the most appropriate range for the patients (Figure 2). 
 
 
 
Fig. 2. Example of a HBS dialysis. The time course of the controlled variables (BV, %, UF 
volume, L), are shown on the top panel, while the actuators (DC, mS/cm and Ultrafiltration 
rate rate, L/h) are shown at the bottom. According to the desired BV and UF vol time 
pattern (the dashed mid line in 1 and 2) the UFR and DC are adjusted time by time by the 
controller to minimize the error between the desired and actual values. At any time their 
maximum and minimum values are maintained within safety limits (dashed lines in the 
bottom panel) As long as the BV, UF Vol and average DC are within the pre-set tolerances 
(dashed lines in the top panel) there is no need to change any set-point (Santoro et al., 2002). 
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Fig. 3. State diagram of two out of the three controlled variables (BV and UF vol) during the 
sample dialysis shown in figure 2. 
Thanks to the continuous adjustment of these parameters according to the dynamically 
changing clinical condition of the patient, the system is also useful to understand the 
refilling capacity of the patients. In fact, it can display the deviation from the set and 
forecasted end dialysis values respectively of the blood volume and UF volume to their set 
points (Figure 3). In particular, the diagram shows, on the horizontal axis, the difference 
between the forecasted end-dialysis BV and its set-point at any minute, while, on the vertical 
axis the difference between the forecasted end-dialysis UF volume and its set-point at any 
minute. It is worth to note that the deviation between the forecasted and set-point lies 
almost always in the upper right quadrant of the diagram. In this case, despite a forecasted 
higher UF volume, the blood volume does not fall down correspondingly, meaning that the 
patient’s refilling capacity is higher than expected. On the contrary, when the state vector is 
in the lower left quadrant, the patient’s refilling capacity seems to be less than expected 
How much this can be attributable to the hydration status (over-hydration or under-
hydration) is still matter of discussion even though there should be a physiological 
dependency behind. 
3. Clinical studies on the hemocontrol™ biofeedback system 
Since the first appearance of an abstract talking about the blood volume monitoring and 
control in the far 1991 Santoro et al., 1991, several studies and papers have been undertaken 
and written. The overall body of this literature is reported in Table 1. 
Many of them are studies showing the clinical benefit of HBS in particular in the reduction of 
hypotension events, some others have been published to explain the underlying mechanisms 
for such a kind of results (Cavalcanti et al, 2004, Severi et al, 2006). We will review the results 
of original clinical trials, which are summarized in Table 2. 
Fifteen studies were prospective, randomised, controlled trials lasting from four weeks to 48 
weeks. In general, study objectives addressed haemodynamic stability during dialysis, 
cardiovascular effects, dialysis efficiency, interdialytic events and quality-of-life aspects. In 
total, the HBS has been used in more than 280 patients who were hypertensive, hypotension-
prone or non-hypotension-prone. The studies were run in Canada and several European 
countries. Actually, 287 patients were treated in the demonstrated clinical studies, ratio 
between male and female was 2.2, the mean age 66.3 years +/- 6.3 years. Diabetes mellitus was 
www.intechopen.com
 
Blood Volume Regulation 239 
observed in 32.16% of all patients, Glomerulonephritis in 29.03%, interstitial nephropathy 
14.3%, IgA nephropathy 7.1%, chronic pyelonephritis 3.6%, other 13.81%. 
 
 
Author Year Journal 
Type of 
publication 
Santoro A et al 1994 ASAIO Trans Clinical Trial 
Santoro A 1995 Nephrol Dial Transplant Editorial 
Mancini E et al 1995 Int J Artif Organs Clinical Trial 
Santoro A et al 1996 Nephrol Dial Transplant Review 
Santoro A et al 1997 Int J Artif Organs Editorial 
Santoro A et al 1998 Am J Kidney Dis Clinical Trial 
Santoro A et al 1998 Nephrol Dial Transplant Review 
Paolini F et al 1999 Adv Ren Replace Ther Review 
Ronco C et al 2000 Kidney Int Clinical Trial 
Basile C et al 2001 Nephrol Dial Transplant Clinical Trial 
Zucchelli P et al 2001 Semin Nephrol Review 
Begin V et al 2002 ASAIO J Clinical Trial 
Pastore C et al 2002 EDTNA ERCA J Clinical Trial 
Santoro A et al 2002 Contrib Nephrol Review 
Santoro A et al 2002 Kidney Int Clinical Trial 
Wolkotte C et al 2002 Nephron Clinical Trial 
McIntyre CW et al 2003 Clin Nephrol Clinical Trial 
Santoro A et al 2003 J Nephrol Review 
Cavalcanti S et al 2004 Kidney Int Clinical Trial 
Franssen CF et al 2005 Hemodial Int Clinical Trial 
Selby NM et al 2006 Am J Kidney Dis Clinical Trial 
Moret K et al 2006 Nephrol Dial Transplant Clinical Trial 
Severi S et al 2006 Hemodial Int Clinical Trial 
Dasselaar JJ et al 2007 ASAIO J Clinical Trial 
Dasselaar JJ et al 2007 J Ren Care Clinical Trial 
Deziel C et al 2007 Clin J Am Soc Nephrol Clinical Trial 
Azar AT 2008 Saudi J Kidney Dis Transpl Review 
McIntyre CW et al 2008 Clin J Am Soc Nephrol Clinical Trial 
Nesrallah GE et al 2008 ASAIO J Clinical Trial 
Santoro A et al 2008 Contrib Nephrol Review 
Winkler RE et al 2008 Contrib Nephrol Clinical Trial 
Table 1. Full list of peer reviewed papers on HBS. 
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Author Patients Study Design Major Results with HBS 
Compared to HD 
P 
Santoro 
et al, 
1994 
hypotension 
prone 
n=5 
Prospective, cross-over 
HD(2wks) – HBS(2wks) – 
HD(2wks)  
Intradialytic  
hypotension ↓ 
Intradialytic symptoms ↓ 
<0.05 
n.s. 
Santoro 
et al., 
19981 
hypotension-
prone 
n=8 
Prospective, cross-over 
HD(4wks)HBS(4wks)HD(4
wks) 
intradialytic stability (SAP)↑ 
hypotensive episodes ↓ 
intradialytic events ↓ 
isotonic saline ↓ 
<0.05 
<0.05 
- 
<0.05 
Ronco et 
al., 20002 
hypotension-
prone 
n=12 
Prospective RCT, cross-over 
HD(2wks)HBS(2wks) vs. 
HBS(2wks)HD(2wks) 
hypotensive episodes ↓ 
saline infusions ↓ 
rebound ↓ (eKt/V↑) 
<0.001 
<0.001 
<0.001 
Basile et 
al., 20013 
hypotension-
prone 
n=19 
Prospective, cross-over 
HD(6mo)HBS(14-30mo)  
HD(4*+3wks)HBS(4*+3wks)
symptomatic  
hypotension ↓ 
muscle cramps ↓ 
post-HD-asthenia ↓(other 
symptoms n.s.) 
vascular refilling ↓ 
<0.002 
<0.02 
<0.0001 
<0.05 
Bégin et 
al., 20024 
hypotension-
prone n=7 
Prospective, cross-over 
3x[HD(2wks)HBS(2wks)] 
event-free sessions ↑ 
mean postdialysis BP ↑ 
<0.01 
- 
Wolkotte 
et al., 
2002 
Unselected 
sample 
N=16 
Prospective, cross-over 
HD(3wks) - HBS(3wks)  
Intradialytic  
hypotension ↓ 
Intradialytic  
symptoms ↓ 
0.033 
0.039 
Santoro 
et al., 
20025 
hypotension-
prone 
n=36 
Prospective RCT, cross-over 
2x[HD(4wks)HBS(4wks)] vs.
2x[HBS(4wks)HD(4wks)] 
intradialytic  
hypotension ↓ 
interdialysis symptoms ↓ 
0.004 
<0.001 
McIntyre 
et al., 
20036 
non-
hypotension-
prone 
n=15 
Prospective, cross-over 
HD(3wks)HBS(2*+3wks) 
symptomatic episodes ↓ 
reductions in systolic BP ↓ 
RBV falling >10% ↓ 
interdialytic weight gain ↓ 
eKt/V ↑, urea clearance ↑ 
<0.001 
- 
<0.001 
0.009 
<0.01 
Franssen 
et al., 
20057 
hypotension-
prone 
n=7 
Prospective, cross-over 
HD(3wks)HBS(3wks)HBS(
6wks)1 
intradialytic hypotension ↓ 
systolic BP ↑ 
no effect on post-HD dry 
weight 
<0.01 
<0.05 
Moret et 
al., 20068 
hypotension-
prone n=12 
Prospective RCT, cross-over 
4 phases: HD, HBS, SP§, PC#2 
hypotensive episodes least 
frequent with HBS  
n.s. 
Selby et 
al., 20069 
hypotension-
prone 
n=8 
Prospective RCT, cross-over 
HD(1*+2wks)HBS(1*+2wks) 
vs. 
HBS(1*+2wks)HD(1*+2wks)
LV regional wall motion 
abnormalities ↓ 
EF ↑ 
haemodynamic data ↑ 
- 
0.043 
<0.05 
Dasselaar 
et al., 
200710 
hypertensive
n=28 
Prospective RCT 
HD(4*+12wks) vs. 
HBS(4*+12wks)  
hypotensive episodes ↓ 
brain natriuretic peptide 
levels ↓ 
predialysis systolic BP ↓  
<0.05 
n.s. 
<0.05 
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Author Patients Study Design Major Results with HBS 
Compared to HD 
P 
Déziel et 
al., 200711 
50% 
hypotension-
prone  50% 
hypertensive
n=36 
Prospective RCT 
HD(4wks*+6mo) vs. 
HBS(4wks*+6mo) 
systolic and diastolic BP ↓ 
intradialytic interventions ↓ 
QoL/KDQOL-SF (burden 
of kidney disease) ↑ 
n.s. 
0.04 
0.004 
Nesrallah 
et al., 
200812 
hypotension-
prone 
n=60 
Prospective RCT 
HD(4wks*+6mo) vs. 
HBS(4wks*+6mo) 
no change in extracellular 
fluid volume 
intradialytic hypotension ↓ 
no change in QoL/dialysis-
related symptoms quest. 
- 
0.04 
- 
Winkler 
et al., 
200813 
hypotension-
prone 
n=18 
Retrospective 
HDHBS(48wks) 
hypotensive episodes ↓ 
muscle cramps ↓ 
eKt/V ↑ 
LVMI ↓ 
EF ↑ 
Antihypertensive drugs ↓ 
<0.01 
<0.01 
<0.05 
<0.01 
n.s 
n.s 
*wash-out/run-in phase; § SP, sodium profiling; # PC, plasma conductivity controlled feedback; ↓, 
reduced; ↑, improved  
1) during first HBS phase post-HD weight remained stable, during second phase reduced target weight 
2) 11 consecutive treatments for each modality followed by 1 week of treatment with standard dialysis 
Abbreviations: RCT, randomised controlled trial; HD: haemodialysis; HBS: HemocontrolTM biofeedback 
system; SAP, systolic arterial blood pressure; n.s., not significant; BP, blood pressure, LV(MI), left 
ventricular (mass index); EF, cardiac ejection fraction. 
Table 2. Summary of the main results of the clinical trias on HBS. 
4. Intradialytic haemodynamic stability 
Based on the European Best Practice Guidelines (EBPG) for hemodynamic instability 
(Kooman et al., 2007) the average incidence of hypotensive episodes during dialysis therapy 
is 20%. In some cohort studies, hypotensive events were observed in up to 33% of cases 
during dialysis therapy. Hypotensive episodes during the course of dialysis therapy are 
closely correlated with morbidity and mortality and play a fundamental role in the 
development of myocardial and cerebral ischemia. Frequent occurrences of hypotension 
lead to chronic over-hydration and have a negative impact on the clearance of dissolved 
substances due to water retention. 
The first study on HBS was run by Santoro in 1994 which was addressed to check the 
feasibility of the system. They included a small sample of five patients in a HD-HBS-HD 
experimental set-up. The occurrence of dialysis complicated by severe hypotension was 8 in 
HD, 1 in HBS and 5 in the second HD period. 
Subsequently, they did another clinical investigation on 8 hypotension-prone patients in a 
prospective crossover study including 8 hypotension-prone haemodialysis patients (Santoro 
et al, 1994). They compared conventional haemodialysis (HD) to the HBS, following a 
protocol with an HD1-HBS-HD2 sequence, with each treatment period lasting one month. 
Changes in predialysis to postdialysis systolic arterial pressure were lower in the HBS 
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period (-12.4%) compared to both HD periods (-20% in HD1 and -17.5% in HD2; P<0.05), 
despite comparable total ultrafiltration rates and mean treatment times. A significant 
reduction in the number of severe hypotensive episodes (HBS: 3, HD1: 26, HD2: 16; P<0.05) 
and fewer intradialytic events, such as cramps and nausea, were observed. This resulted in a 
reduced need for therapeutic isotonic saline in each session (HBS: 60 mL, HD1: 160 mL, 
HD2: 95 mL; P<0.05). 
The first randomised, controlled trial on HBS was published by Ronco (Ronco et al, 2000), 
who treated 12 hypotension-prone patients with either 2 weeks of HD followed by 2 weeks 
of HBS or vice versa (6 session per patient and 72 in total). They also observed fewer 
hypotensive episodes with HBS (24/72 vs 59/72 in HD; P<0.001). Saline infusion was 
required in 15 cases during HBS in comparison to 57 cases during HD (P<0.001). 
Medium-term treatment with HBS was evaluated in a prospective study published by Basile 
(Basile et al., 2001). They investigated the efficacy and safety of HBS vs conventional HD in 
19 hypotension-prone uraemic patients. After a period of 6 months on HD, patients 
switched to HBS for 14 to 30 months. A wash-out phase of 4 weeks was followed by a short-
term treatment period of 3 weeks, first with HD and then after wash-out with HBS. The 
overall occurrence of symptomatic hypotension and muscle cramps was significantly 
reduced, with a decrease of 34% and 40% respectively (P-values: <0.002 and <0.02 
respectively). In the short-term part of the study, the vascular refilling (residual 
BV%/ECV% ratio) was significantly higher during the HBS treatment. 
Several other groups have been shown improvement in haemodialysis-induced hypotension 
in hypotension-prone patients [Santoro et al., 2002; Franssen et al., 2005; Selby et al., 2006; 
Moret et al., 2006; Dasselaar et al., 2007; Neshrallah et al; Winkler et al., 2008). 
Ambulatory blood-pressure measurement in one prospective trial revealed that during the 
first 16 hours post-HD, systolic blood pressure was significantly higher with HBS in 
comparison to conventional HD (Franssen et al., 2005). Other trials showed a significant 
overall decrease in systolic blood pressure in both groups during the study period (P=0.005 
vs the baseline) (Deziel et al., 2007). However, the difference between the HD and HBS arms 
was not significant. 
Attempts to correct extracellular fluid volume (ECFV) with aggressive ultrafiltration often 
leads to intradialytic hypotension. Therefore, it was of interest to see whether HBS treatment 
could safely reduce ECFV in extracellular fluid-expanded patients (Neshrallah et al., 2008). 
However, the results of this randomised trial revealed no change with HBS, even after 
multivariate adjustment. 
Bégin et al. investigated whether improvement in hypotension-related events can be 
explained by changes in dry weight (Begìn et al., 2002). In their prospective trial in 7 
hypotension-prone patients, they observed the greatest improvement in event-free sessions 
(i.e. sessions not requiring therapeutic intervention for hypotension-related signs and 
symptoms) in patients who had the smallest changes in dry weight. This is supported by 
other studies, which revealed that HBS was not effective in reducing post-HD dry weight 
(Fransesen et al, 2005, Dasselaar et al., 2007). A randomised, controlled trial demonstrated 
that the best responders to HBS treatment were those with higher predialysis systolic blood-
pressure values compared to poor responders (P=0.04) (Santoro et al., 2002). 
While most data on HBS were obtained from the study of hypotension-prone patients, one 
trial was especially designed to look at the effects in non-hypotension-prone uraemic 
patients (McIntyre et al., 2003). During this prospective study, 15 patients received 
conventional HD over 3 weeks followed by a 2-week wash-out phase and an HBS-treatment 
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phase over 3 weeks. There was a reduction in symptomatic episodes (per patient over 3 
weeks) from 3 during HD to 0.13 with HBS (P<0.001). The number of treatments affected 
by a reduction of > 40% in systolic blood pressure decreased from 1.4 to 0.46 and episodes 
during which relative blood volume fell by > 10% were reduced from 6.3 to 1.13 per patient 
and treatment period (P<0.001). The treatment of 28 hypertensive patients with either 
standard HD or HBS in a randomised manner showed significantly fewer hypotensive 
episodes, lower brain natriuretic peptide levels (not significant) and a significant reduction 
in predialysis blood pressure in the HBS group (Neshrallah et al., 2008). 
5. Pooled analysis about intradialytic cardiovascular stability 
Since, most of the studies, addressed the intradialytic hypotension, we summarized the data 
about the cardiovascular instability (intradialytic hypotension and weight loss) in the 
following pooled analysis. We included all the studies of any type (random cross-over, 
random not cross over and not random), which reported available data in form of 
percentage of dialysis complicated by hypotensions or average frequency of hypotension 
events, disregarding this was or was not the primary response variable. 
 
 
 
Fig. 4. Pooled analysis of intradialytic hypotensions. The figure shows the hypotension 
events expressed as mean ± SD over the total number of dialysis. 
We did not include in the analysis those studies for which confounding factors like 
hemodiafiltration and/or acetate free biofiltration, cold dialysate temperature if not present 
both in the intervention and control treatments could interfere with data interpretation. 
For each study we extracted the total number of treatments performed both with standard 
and HBS hemodialysis and the total events (dialysis complicated by hypotensions or major 
hypotension events) for each one, or the meanSD hypotension events as reported in the 
paper. 
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Figure 4 shows the results of the pooled analysis about the intradialytic hypotension of the 
thirteen included studies in the analysis. The reported data refer to 2520 dialysis in HBS 
against 2130 dialysis in conventional dialysis. 
The overall mean difference was nearly -12% favoring the HBS treatment with an estimated 
range between -15% and -8%. The range is almost narrow despite some studies showed 
wider ranges (Dasselaar et al., 2007). 
Discrepancies between the single studies can be partially explained by: a) the difference in 
within study variance underlying the difference in the sample size (from 8 to 44 recruited 
patients), b) the difference in the study design (cross-over, parallel group, etc) c) the target 
population (hypotension prone, non-hypotension prone and hypertensive patients), d) the 
difference in the between study reflecting the difference in the primary response variable 
(blood pressure drop, fluid overload) leading sometimes to a bias in the dialysis complicated 
by hypotension variable, e) the length of follow up ranging from few weeks to two years. 
These good results are emphasized by looking at the weight loss during dialysis in the two 
treatments as reported in Figure 5. The overall result shows a higher weight loss in HBS 
than in standard treatment equal to 160 g. All the authors reported this behavior even 
though some were not statistically significant. McIntyre indeed report the interdialytic 
weight gain, which could not properly reflect the weight loss during the follow-up. 
 
 
 
Fig. 5. Body weight loss during dialysis. Data report the pre to post dialysis body weight 
change during dialysis (in Kg or L) expressed as mean SD over the total assessed dialysis. 
Different alternatives are available to reduce or prevent the noticeable drop in blood 
pressure during the extracorporeal therapy. In this context, the time and frequency of 
dialysis play a significant role, but the time of dialysis cannot be infinitely expanded because 
of socioeconomic framework conditions. Regulating the blood temperature via dialysate 
temperature can also have a noticeable positive effect on the blood pressure management. 
To what extent the efficacy of the therapy is limited because of the higher peripheral overall 
resistance is the subject of further studies. On-line hemodiafiltration is another established 
possibility to prevent a drop in blood pressure during blood purification therapy. The high 
convective rate of this procedure is capable of achieving the stabilisation of the blood 
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pressure. However, during the first half of the therapy time with in-line hemodiafiltration, 
HBS is also characterised by a high convective dialysis rate. The recommended increase of 
the dialysate calcium concentration to 1.5 mmol/L should be considered with caution 
because it may result in a significant elevation of the calcium x phosphate product. HBS 
works with ultrafiltration control and sodium management to realise better refilling of the 
intravascular compartment. 
The short reaction time of the MiMo (Multi input - Multi output) controller (Figure 2) 
guarantees the prevention of a hypotensive event or reduces its intensity. The underlying 
mechanisms should be found both in the fast reaction of the system to rapid blood volume 
drops and in the pre-set pathway which avoid the achievement of risky patient dependent 
blood volume thresholds. 
6. Electrolyte implications 
The electrolyte implication of HBS have been included in some of the studies and deeply 
investigated in one paper by Moret (Moret et al., 2006). 
In this study they compared the effect of sodium manual profiling and automatic profiling 
versus standard treatment on the sodium mass balance measure through its surrogate 
variable, the ionic mass balance. It is interesting the comparison between standard dialysis 
prescribed at 140 mMol/L and biofeedback technologies (HBS and biofeedback on plasma 
conductivity) prescribed at equivalent values of 14.0 mS/cm. The manual profiling was 
indeed, prescribed with a linear time course starting at 15.0 mS/cm and ending at 14.0 
mS/cm. The ionic mass balance in each study session was 423166 mMol, 488179 mMol 
and 409109 mMol respectively in standard, HBS and plasma conductivity biofeedback. 
Other studies on HBS reported data about the post dialysis natremia. Despite they did not 
investigated the actual sodium mass removal, they found no differences between standard 
versus HBS sessions. Santoro in 1998 reported end dialysis natremia equal to 1461.5 
mMol/L in standard hemodialysis and 146.21.1 in HBS. They did not showed the 
predialysis natremia then one cannot conclude that the ionic mass balance could have been 
similar in the two treatments. Moreover, this was a short term study and a potential sodium 
overload could not have been seen. Subsequently the same group published a multicenter 
study (Santoro et al, 2002) in which data about the pre and postdialysis natremia were 
shown. Pre and post-dialysis plasma sodium values were: 138.70.5 and 141.80.6 in 
standard HD and 138.8 .6 and 141.30.7 in HBS. Moreover, if we consider that actual 
weight loss, blood flow rate and treatment time were equal in both the treatment, we could 
argue that the sodium mass balance should have been similar in the two treatment. Similar 
results in short-term study were reported by Wolkotte (Wolkotte et al, 2002). Pre and Post 
dialysis sodium levels were 139.82.5, 141.21.8 in standard HD and 139.62.4, 141.31.8 in 
HBS respectively and corresponding to weight loss of 2.40.7 in HD and 2.50.8 in HBS. 
Mid-term results were reported only in the study by Dasselaar (Dasselaar et al., 2007). The 
follow-up lasted 12 week per group (HD and HBS) and the values were at the end of the 
follow-up were: 139.22.5, 139.82.1 in HD and 139.82.2, 139.92.1 in HBS. Then, they 
observed an increase of 1 mMol/L in the postdialysis natremia but, the actual wight loss 
was 2.76.7L in HD while 3.16.5L in HBS even though not statistically significant. 
In conclusion, the several authors who investigated this aspect did not find any potential 
sodium overload in HBS. This is due to the underlying mathematical sodium kinetics model 
used to regulate the sodium mass balance in the form of equivalent conductance. 
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7. Cardiac effects of haemodynamic stability 
Cardiac failure and the rate of cardiovascular mortality are extremely high in dialysis 
patients. One of the major causes of heart failure in these patients is probably recurrent 
subclinical myocardial ischemia. Selby et al. examined whether this occurs in response to 
stress of haemodialysis and whether it can be reduced by improved hemodynamic stability 
with HBS treatment (Selby et al., 2006). Eight hypotension-prone patients were included in a 
randomised cross-over trial to compare the development of left-ventricular regional-wall 
motion abnormalities during HBS treatment and standard HD. There were 42 regional-wall 
motion abnormalities during HD vs 23 during HBS (odds ratio 1.8; 95% CI: 1.1 to 3.0). The 
majority of these abnormalities improved in function within 30 minutes after dialysis 
(Figure 7). At peak stress, ejection fraction was significantly lower during HD (P=0.043). 
Haemodynamic parameters, such as pulse rate, stroke-volume decrease, cardiac output 
decrease, peripheral resistance and mean baroflex sensitivity, were all significantly 
improved during HBS vs HD. We noted comparable results in a retrospective analysis of 18 
patients after 48 weeks of HBS treatment (Winkler et al., 2008): ejection-fraction increase, 
though not significant, and a decrease in left ventricular-mass index (P<0.05). In addition, 
the use of antihypertensive drugs decreased (Figure 7). Two other groups looked at the 
effect of HBS treatment on antihypertensive drug use (Dasselaar et al. 2007, Neshrallah et 
al., 2008). Dasselaar et al. showed that the defined daily dose (DDD) of antihypertensive 
drugs decreased (not significantly) in the HBS group, whereas it was stable in the control 
HD arm (Dasselaar et al., 2007). Nesrallah et al. observed no change in antihypertensive 
drug use in their randomised controlled trial (Neshrallah et al., 2008). 
 
 
Fig. 6. Analysis of left ventricular wall motion in one patients during conventional (HD) and 
biofeedback dialysis (BFD). Arrows indicates the regional wall motion abnormalities which 
persist even after the end of the treatment (Selby et al., 2006). 
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8. Efficiency of treatment 
Effects of the achieved cardiovascular stability were accompanied by an improved efficiency 
of treatment. A lower urea rebound was observed during the HBS sessions, resulting in a 
higher equilibrated Kt/V (eKt/V) as shown by several groups (Ronco et al., 2000, McIntyre 
et al., 2003, Dasselaar et al., 2007, Neshrallah et al., 2008, Winkler et al. 2008). 
In hypotension-prone patients, total urea removed was significantly higher during HBS 
compared to HD sessions (Ronco et al., 2000). This was also demonstrated for non-
hypotension-prone patients. The eKt/V ratio increased from 1.01 ± 0.03 to 1.13 ± 0.03 with 
HBS (P<0.01) (McIntyre et al., 2003) In this group of patients, the mass of urea removed 
increased from 24.9 to 32.7 (P<0.01). 
9. Interdialytic events 
The effect of HBS on interdialytic symptoms, such as muscle cramps, headache, dizziness, 
thirst, dyspnoe, angina, vomiting, itching, the need to lie down, anorexia and asthenia, was 
analysed by Santoro (Santoro et al., 2002) They looked at the number of symptoms between 
2 consecutive sessions within the first 6 hours from the end of dialysis (early symptoms) and 
later until the beginning of the next dialysis session (late symptoms) and observed a 10% 
overall reduction (P<0.001) in symptoms after treatment with HBS. 
10. Quality of life 
Déziel et al. investigated the impact of HBS treatment on health-related quality of life 
(Deziel et al., 2007). They included 44 patients who were partially hypertensive and/or 
hypotension-prone in a 6-month randomised controlled trial comparing standard HD and 
HBS. Quality of life was assessed using the Kidney Disease and Quality of Life Short 
Form (KDQOL-SF) questionnaire. There was a significant improvement in the burden of 
 
 
Fig. 7. Decrease of antihypertensive drug and end dialysis body weight over 48 months of 
follow-up. 
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kidney disease score in the HBS group, while there was a decrease in the control group 
(P=0.004). There was no other significant variation in quality-of-life items during the 
study. In another randomised trial comparing 6-month HD vs HBS treatment, a validated 
dialysis-related symptoms questionnaire was used to assess dialysis-related quality of life 
(Neshrallah et al., 2008). This questionnaire asked patients to rate the frequency and 
severity of dizziness, fatigue, muscle cramps, and other symptoms. None of these differed 
significantly between groups over time. 
11. Conclusions 
The growing number of patients with CKD/KDOQI stage 5D is characterised by higher age 
and increasing comorbidities such as arterial hypertension, diabetes mellitus, 
arteriosclerosis and atherosclerosis, coronary heart disease as well as peripheral arterial 
perfusion impairments. In the large majority of patients, age and morbidity-related vascular 
alterations result in a reduced refilling capacity from the extracellular and intracellular 
compartment into the intravasal compartment.  
The divergence between ultrafiltration and absent refilling can lead to severe hypotensive 
events during the course of the dialysis. Incidence and intensity of hypotensive 
complications are correlated with morbidity, frequency of hospitalisation, myocardial and 
cerebral ischemia and consecutively with mortality. 
The complications are preventable by increasing the dialysis time and frequency, decreasing 
the dialysate temperature, increasing the dialysate calcium concentration and/or with on-
line hemodiafiltration. Nonetheless, dialysis time and frequency are finite, and affects the 
staff and unit workload, while elevated dialysate calcium concentrations could lead to 
positive mass balance with cumulative calcium overload exposing the patients to higher risk 
of valvolar and vascular calcification. Nevertheless, hemodiafiltration, due to the high 
efficiency and high solute extraction, can yield to transient electrolyte and osmolar 
disequilibrium (Ursino et al, 1997) opposing to plasma refilling and exposing to higher risk 
of electrical disequilibrium and cardiac dysrhythmias especially in fragile patients, Then, 
HBS lends itself as a gentle and effective procedure to improve the refilling capacity, to 
prevent hypotensive events and to optimize the post-dialysis weight. Under HBS, arterial 
hypertension was improved, dialysis therapy more effective, the body weight optimised, the 
myocardial function improved, the risk of intradialytic hypotension lower and the patients‘ 
quality of life during intradialytic and interdialytic intervals improved. 
HBS is a treatment option for elderly, morbid dialysis patients. 
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